Navigation Links
Alnylam Announces Advancement of a New RNAi Therapeutic Development,Program for the Treatment of Liver Cancer

peutics based on RNA interference, or RNAi. The company is applying its therapeutic expertise in RNAi to address significant medical needs, many of which cannot effectively be addressed with small molecules or antibodies, the current major classes of drugs. Alnylam is building a pipeline of RNAi therapeutics; its lead program is in Phase I human clinical trials for the treatment of respiratory syncytial virus (RSV) infection. RSV infects nearly every child at least once by the age of two and accounts for more than 100,000 hospitalizations annually in the U.S. pediatric population. RSV infection also poses a great risk to the elderly and other adults with compromised immune systems. The company's leadership position in fundamental patents, technology, and know-how relating to RNAi has enabled it to form major alliances with leading companies including Merck, Medtronic, Novartis, and Biogen Idec. The company, founded in 2002, maintains global headquarters in Cambridge, Massachusetts, and has an additional operating unit in Kulmbach, Germany. For more information, visit www.alnylam.com.

Alnylam Forward-Looking Statements

Various statements in this release concerning our future expectations, plans, and prospects, including statements concerning the timing of filing an IND for ALN-VSP01, statements concerning use of RNAi therapeutics for the treatment of liver and other cancers, statements concerning use of siRNAs to achieve therapeutic silencing of genes and statements concerning effective delivery of siRNAs, constitute forward-looking statements for the purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, including risks related to: our approach to discover and develop novel drugs, which is unproven and may never lead to marketable products; our ability to fund and the results
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. Alnylam Reports Results of Human Experimental Infection Model with Respiratory Syncytial Virus
2. Alnylam and Stanford University Scientists Discover New Role for microRNAs (miRNAs) in T Cell Biology and Immunity
3. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
4. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
5. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
6. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
7. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
8. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
9. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
10. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
11. Protox Announces Positive Clinical Data from Prostate Cancer Study
Post Your Comments:
(Date:8/22/2014)... 22, 2014  Dr. Mark Rasak , MD ... Lifetime Achievement Award in the field of Medicine as ... Clinical Associates. Dr. Rasak has over 15 ... aspects of the business; overseeing the daily operations; interventional ... intervention. In addition, he is an honored Fellow of ...
(Date:8/22/2014)... Research and Markets has announced the addition ... Report 2014" report to their offering. ... 2014 is a professional and in-depth study on the ... a focus on the Chinese situation. The report ... classifications, applications and industry chain structure. The intravenous catheter ...
(Date:8/22/2014)... -- Research and Markets has announced the ... Industry Report 2014" report to their offering. ... Report 2014 is a professional and in-depth study on ... with a focus on the Chinese situation. The ... definitions, classifications, applications and industry chain structure. The particulate ...
Breaking Medicine Technology:Dr. Mark Rasak, MD is recognized by Continental Who's Who with the Diamond Lifetime Achievement Award 2Global and Chinese Intravenous Catheter Industry Report 2014 2Global and Chinese Particulate Respirators Industry Report 2014 2
... Ind., Aug. 18, 2011 Symmetry Medical Inc. (NYSE: ... innovative medical device solutions, including orthopedic implants, surgical instruments, ... has completed the previously announced acquisition of Olsen Medical. ... in the design, development and manufacturing of electrosurgical instruments ...
... 18, 2011 According to the Arthritis ... in the United States and is one of the ... Pet owners can easily be overwhelmed by the variety ... symptoms. NationalPetPharmacy.com provides the following nutritional recommendations ...
Cached Medicine Technology:Symmetry Medical Closes Olsen Medical Acquisition 2Tips for Reducing the Signs of Arthritis in Pets 2Tips for Reducing the Signs of Arthritis in Pets 3
(Date:8/22/2014)... August 22, 2014 AWeber, one ... that currently helps more than 120,000 small businesses ... the attention of Shane Michaels, prompting an investigative review. ... element for any online marketing campaign, despite what some ... the marketing world,” reports Michaels. “AWeber is a great ...
(Date:8/22/2014)... 2014 Buying a policy for different life ... unsure about available coverage types by insurers in the U.S. ... policy pricing to the public using its sortable tool at ... is free and is expected to promote the discounts and ... throughout the U.S. The system is designed to help an ...
(Date:8/22/2014)... The regional economy is about to get ... the grow again. The plant will invest $100 ... boost production of the popular Highlander midsize sport utility ... to $4 billion. This step allows Toyota to utilize ... to adjust its product mix to meet changing customer ...
(Date:8/22/2014)... York (PRWEB) August 22, 2014 ... morcellators ( http://www.injurybeacon.com/power-morcellator/ ) in uterine surgeries continues ... Massachusetts insurance companies have decided to limit coverage ... the Worcester Telegram, Blue Cross-Blue Shield of Massachusetts ... surgeries that involve morcellation as of September 1, ...
(Date:8/22/2014)... 11 (BIM) deletion in advanced non-small cell lung ... survival (PFS) in epidermal growth factor receptor (EGFR) ... patients. Also, BIM deletion independently predicts overall survival ... protein can activate the programmed cell death also ... deletion has been detected in 12.8% of the ...
Breaking Medicine News(10 mins):Health News:AWeber: Review Exposes Affordable Provider of Opt-In Email Marketing Services 2Health News:Principal Life Insurance Policies Now Quoted for Adults at Insurance Website Online 2Health News:Toyota Indiana Adding 300 Jobs to Build More Highlanders 2Health News:As Power Morcellator Controversy Grows, Bernstein Liebhard LLP Comments on Massachusetts Insurers’ Plans to Limit Coverage of Uterine Morcellation 2Health News:As Power Morcellator Controversy Grows, Bernstein Liebhard LLP Comments on Massachusetts Insurers’ Plans to Limit Coverage of Uterine Morcellation 3Health News:As Power Morcellator Controversy Grows, Bernstein Liebhard LLP Comments on Massachusetts Insurers’ Plans to Limit Coverage of Uterine Morcellation 4Health News:Deletion predicts survival in advanced non-small cell lung cancer 2
... organization will leverage Risk MonitorPro, (R) ... patient feedback and adverse events,CAMBRIDGE, MA, ... of healthcare quality and safety software, announced today that ... patient safety and quality of care initiatives. , Named ...
... poised to enter Animal Health Rapid Diagnostics Market with ... Jan. 13 Abaxis, Inc. (Nasdaq: ABAX ... instruments for both the medical and veterinary markets, announced ... Scientific for the manufacturing of a Canine Heartworm Lateral ...
... Association (NEA) awarded its Seal of Acceptance to ... NEA Seal of Acceptance is part of the association,s ... to improve the quality of life for people who ... our criteria for having no irritating ingredients and being ...
... Insurance Reports Job Opportunities for Commissioned Insurance Sales Agents Across the ... ... 2009 -- Despite recent reports by the U.S. Bureau of Labor ... continue throughout 2009, Combined Insurance, a leading provider of supplemental ...
... device can be used in home, rather than hospital, and can ... ... (PRWEB) January 13, 2009 -- MedFaxx has announced ... combines the most used form of electrotherapy in the world clinically ...
... on its recent analysis of the autoimmune disease ... with the 2008 European Frost & Sullivan Excellence ... incorporation of synthetically modified peptides for the validation ... autoimmune diseases and is also looking to adopt ...
Cached Medicine News:Health News:Woman's Hospital Selects rL Solutions for Improved Adverse Event and Patient Safety Reporting 2Health News:ABAXIS Announces Contract Manufacturing Agreement with SA Scientific, Ltd. 2Health News:ABAXIS Announces Contract Manufacturing Agreement with SA Scientific, Ltd. 3Health News:National Eczema Association Anoints Theraplex Products with Seal of Acceptance 2Health News:Leading Insurer Reports Positive Outlook for U.S. Insurance Industry Jobs in 2009 2Health News:Leading Insurer Reports Positive Outlook for U.S. Insurance Industry Jobs in 2009 3Health News:North Carolina Company Announces First Chronic Pain Control Unit Combining Two Most Used Forms of Electrotherapy For Chronic Pain - Tens & Interferential 2Health News:North Carolina Company Announces First Chronic Pain Control Unit Combining Two Most Used Forms of Electrotherapy For Chronic Pain - Tens & Interferential 3Health News:Frost & Sullivan Lauds Toscana Biomarkers' Outstanding Contributions to the R&D of Novel Biomarkers for the Diagnosis of Autoimmune Diseases 2Health News:Frost & Sullivan Lauds Toscana Biomarkers' Outstanding Contributions to the R&D of Novel Biomarkers for the Diagnosis of Autoimmune Diseases 3Health News:Frost & Sullivan Lauds Toscana Biomarkers' Outstanding Contributions to the R&D of Novel Biomarkers for the Diagnosis of Autoimmune Diseases 4
... For use in the percutaneous retrieval of indwelling ... wire guides, and other foreign objects. A ... around the lead body. It is delivered to ... flexible 12 Fr cannula that is placed coaxially ...
... Novalis, BrainLAB's dedicated ... radiosurgery and radiotherapy (SRS/SRT), ... highly precise treatments of ... head & neck tumors, ...
The Radionics XKnife RT2 system provides a precise and versatile stereotactic radiation therapy solution....
Clinac EX Platinum accelerators offer all the high performance features of the EX series and come with the latest high-precision dose sculpting technology for advanced tumor control....
Medicine Products: